GLP-1 Drug Development
Clinical development, competitive landscape, and market dynamics of GLP-1 receptor agonist medications and related obesity/diabetes drug combinations.
3 events tracked
Latest in GLP-1 Drug Development· Oct 20
Novo Nordisk's experimental obesity injection achieved 25% weight reduction in female trial participants, expanding the company's pipeline beyond its established diabetes franchise. Success in late-stage testing positions the drug for potential regulatory submission, though approval timing and real-world adoption rates remain uncertain. Widening GLP-1 use reshapes demand across food, beverage, and wellness sectors as treatment penetration increases among eligible populations.
- Single source2 days ago
Novo's experimental obesity injection produces quarter bodyweight reduction in women
Novo disclosed that CagriSema, an experimental injection, achieved greater weight reduction than its existing Wegovy treatment in late-stage testing.
CNBC
- Single source20 days ago
Eli Lilly and Novo Nordisk pursue amylin-based treatments for obesity
Eli Lilly and Novo Nordisk are developing amylin-based obesity drugs to follow their GLP-1 successes.
CNBC
- Single source22 days ago
Eli Lilly's dual-drug obesity treatment demonstrates stronger weight reduction in Phase 2
Eli Lilly's combination obesity treatment shows improved weight loss results in mid-stage trial.
CNBC